Malignant insulinoma presenting a non-functioning metastatic liver tumor 14 years after resection of the primary tumor

1998 ◽  
Vol 33 (6) ◽  
pp. 891-894 ◽  
Author(s):  
Masakazu Kobayashi ◽  
Shigeyuki Kawa ◽  
Masanori Kobayashi ◽  
Yutaka Imai ◽  
Takeshi Sodeyama ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Primary Tumor ◽  
Metastatic Liver Tumor ◽  
Malignant Insulinoma ◽  
Metastatic Liver

scholarly journals Esophageal Large-Cell Neuroendocrine Carcinoma with Inconsistent Response to Treatment in the Primary and Metastatic Lesions

2018 ◽  
Vol 12 (2) ◽  
pp. 234-239 ◽  
Author(s):  
Takashi Tomiyama ◽  
Masahiro Orino ◽  
Koh Nakamaru ◽  
Toshihiro Tanaka ◽  
Ryo Suzuki ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Malignant Tumor ◽  
Liver Tumor ◽  
Primary Tumor ◽  
Metastatic Tumor ◽  
Large Cell ◽  
Metastatic Liver Tumor ◽  
Pathological Findings ◽  
Metastatic Lesions ◽  
Metastatic Liver

Esophageal large-cell neuroendocrine carcinoma (NEC) is a rare malignant tumor that is characterized by high-grade malignancy and a poor prognosis. However, the rarity of esophageal NEC has prevented the development of an established treatment, and no reports have described a discrepancy in the effectiveness of cisplatin plus irinotecan between primary and metastatic lesions. A 43-year-old Japanese man was referred to our hospital with refractory epigastralgia. A previous gastrointestinal endoscopy had revealed a 50-mm type 2 tumor in the abdominal esophagus. The pathological findings indicated poorly differentiated squamous cell carcinoma. Contrast-enhanced computed tomography revealed a metastatic liver tumor. One cycle of fluorouracil and cisplatin was not effective, and endoscopy was repeatedly performed. The pathological findings indicated a large-cell malignant tumor with tumor cells that were positive for CD56, synaptophysin, and Ki-67 (> 80%). Based on a diagnosis of esophageal large-cell NEC with a metastatic liver tumor, the patient received cisplatin plus irinotecan biweekly. After 4 months, computed tomography revealed marked shrinkage of the metastatic tumor, but the patient complained of dysphagia. Endoscopy revealed enlargement of the primary tumor, which was then treated using radiotherapy plus fluorouracil and cisplatin. The primary tumor subsequently shrank, and the patient’s symptoms were relieved, but the metastatic tumor grew. Thus, chemoradiotherapy could be an option for managing a primary esophageal large-cell NEC that does not respond to chemotherapy alone. However, the possibility of an inconsistent response to therapy in primary and metastatic lesions should be considered.

A huge metastatic liver tumor from leiomyosarcoma of the inferior vena cava: report of a case

Surgery Today ◽  
2011 ◽  
Vol 42 (5) ◽  
pp. 505-508 ◽  
Author(s):  
Masakazu Hashimoto ◽  
Tsuyoshi Kobayashi ◽  
Hirotaka Tashiro ◽  
Hironobu Amano ◽  
Akihiko Oshita ◽  
...  
Keyword(s):  
Inferior Vena Cava ◽  
Liver Tumor ◽  
Inferior Vena ◽  
Vena Cava ◽  
Metastatic Liver Tumor ◽  
Metastatic Liver

scholarly journals Laparoscopic microwave coagulo-necrotic therapy for metastatic liver tumor

1995 ◽  
Vol 13 ◽  
pp. 63-68
Author(s):  
Tsuneo Tanaka ◽  
Eizo Okamoto ◽  
Naoki Yamanaka ◽  
Takeshi Oriyama ◽  
Jiro Fujimoto ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Metastatic Liver Tumor ◽  
Metastatic Liver

Surgical Resection of Solitary Metastatic Liver Tumor Arising From Lung Cancer: A Case Series

2012 ◽  
Author(s):  
Junji Ueda ◽  
Hiroshi Yoshida ◽  
Yasuhiro Mamada ◽  
Nobuhiko Taniai ◽  
Sho Mineta ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Resection ◽  
Liver Tumor ◽  
Case Series ◽  
Metastatic Liver Tumor ◽  
Metastatic Liver

Treatment strategy for colorectal liver metastases: Clinical impact of FOLFOXIRI regimen for unresectable cases.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 780-780
Author(s):  
Yuji Morine ◽  
Mitsuo Shimada ◽  
Satoru Imura ◽  
Tetsuya Ikemoto ◽  
Shuichi Iwahashi ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Treatment Strategy ◽  
Curative Resection ◽  
Molecular Target ◽  
Metastatic Liver Tumor ◽  
Maximum Diameter ◽  
Remnant Liver ◽  
Conversion Surgery ◽  
Metastatic Liver ◽  
Better Than

780 Background: Recent advances in systemic chemotherapy, including molecular target agents, can introduce “Conversion surgery” and achieve R0 resection even for initially unresectable colorectal liver metastasis (CRLM). We investigated the optimal indication for initial surgical induction and treatment strategy for unresectable CRLM. Methods: Our current surgical indication for CRLM as follows: i) curative resection is achievable, ii) no limitation of tumor size and number, and iii) future remnant liver volume over 35%. Additionally, same indication is applied even after chemotherapy.Two hundreds forty-one cases from 1994 to 2015, consisted of 134 initially resectable case and 107 unresectable cases, were included. Among 107 unresectable cases, 55 cases received current chemotherapy such as FOLFOX, FOLFILI, XEROX and FOLFOXIRI. Results: 1) Optimal indication for initially resectable case:Multivariate analysis revealed MDN (Maximum Diameter × Number) index more than 30 of metastatic liver tumor (HR3.06), non-curative resection of metastatic liver tumor (HR4.082) and poor differentiation of primary tumor (HR11.14).2) Treatment strategy of unresectable case for “Conversion surgery” (FOLFOXIRI vs. other regimen): Forty-two unresectable cases with MDN > 30 were included. Of those 14 cases, FOLFOXIRI regimen was applied. Regarding clinicopathological factors, the use of molecular targeted drug was introduced in all patients of FOLFOXIRI group, but 67.9% patients of other regimen group. The “Conversion” rate in FOLFIXIRI group and other regimen group were 64.3% and 39.3% (p = 0.126), and median period until “Conversion” were 6.2 courses and 11.8 courses (p = 0.038). Regarding tumor necrotic rate, FOLFOXIRI regimen induced higher necrotic rate than other regimen group (77.9% vs. 50.4%, p = 0.073). Overall survival in FOLFOXIRI group has been better than that in other regimen group and 3-years survival rates were 83.3% and 48.0% (p = 0.044). Also, relapse free survival in FOLFOXIRI group was significantly better than that in other regimen group (p = 0.002). Conclusions: MDN can predict surgical outcome for CRLM. FOLFOXIRI plus molecular target drug may be a promising option for CRLM with MDN > 30.

Transplant Oncology in Primary and Metastatic Liver Tumor

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Gonzalo Sapisochin ◽  
Taizo Hibi ◽  
Christian Toso ◽  
Kwan Man ◽  
Marina Berenguer ◽  
...  
Keyword(s):  
Liver Tumor ◽  
Metastatic Liver Tumor ◽  
Metastatic Liver
Sign in / Sign up

Export Citation Format

Share Document